WuXi Biologics (Cayman) Inc 2025 AR2
The report highlights WuXi Biologics' solid business growth in 2025, achieving a 16.7% year-on-year revenue growth and expanding its total backlog to US$23.7 billion. The company added 209 new integrated projects, bringing its total to 945, and successfully completed 28 Process Performance Qualification projects with a 100% success rate. WuXi Biologics also advanced its global manufacturing footprint, including progress on facilities in Chengdu, Singapore, Ireland, and the U.S. Furthermore, the company strengthened its ESG practices, receiving validation from the Science Based Targets initiative for its near-term and net-zero greenhouse gas emissions reduction targets.
Company: WuXi Biologics (Cayman) Inc
Sector: Professional & technical services
Country: China
Year: 2025
Type: AR2
Pages: 263
Back to company
WuXi Biologics (Cayman) Inc
Annual Report
The report highlights WuXi Biologics' solid business growth in 2025, achieving a 16.7% year-on-year revenue growth and expanding its total backlog to US$23.7 billion. The company added 209 new integrated projects, bringing its total to 945, and successfully completed 28 Process Performance Qualification projects with a 100% success rate. WuXi Biologics also advanced its global manufacturing footprint, including progress on facilities in Chengdu, Singapore, Ireland, and the U.S. Furthermore, the company strengthened its ESG practices, receiving validation from the Science Based Targets initiative for its near-term and net-zero greenhouse gas emissions reduction targets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees